HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ZK 200775

structure in first source

Also Known As:

(1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-(trifluoromethyl)quinoxalin-1-yl)methylphosphonate; ZK-200775; ZK200775

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - ZK 200775: 5
Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - ZK 200775: 5

Experts

1.	De Keyser, Jacques: 2 articles (01/2005 - 12/2002)
2.	Diener, Hans C: 2 articles (01/2005 - 12/2002)
3.	Kaste, Markku: 2 articles (01/2005 - 12/2002)
4.	Versavel, Mark: 2 articles (01/2005 - 12/2002)
5.	Bergholz, Richard: 1 article (08/2010)
6.	Rüther, Klaus: 1 article (08/2010)
7.	Staks, Thomas: 1 article (08/2010)
8.	Hommel, M: 1 article (01/2005)
9.	Lees, K R: 1 article (01/2005)
10.	Steiner, Heike: 1 article (01/2005)

Related Diseases

1.	Ischemic Stroke 01/01/2005 - "We tested the safety and tolerability of ZK 200775 in patients with acute ischaemic stroke. " 01/01/2005 - "The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study." 01/01/2005 - "The AMPA antagonist ZK 200775 reversibly worsened the neurological condition in patients with acute ischaemic stroke. " 12/01/2002 - "The AMPA antagonist ZK200775 transiently worsened the neurological condition in patients with acute ischemic stroke. " 12/01/2002 - "AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels."
2.	Stroke (Strokes) 01/01/2005 - "Our results suggest that ZK 200775 exerts significant sedative effects in patients with acute stroke which preclude its further development as a neuroprotective agent in this indication." 09/01/1998 - "ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma."
3.	Craniocerebral Trauma (Head Injury) 09/01/1998 - "ZK200775 alleviated also both cortical and hippocampal damage induced by head trauma in the rat. " 01/01/2000 - "Phosphonate quinoxalinedione derivatives ZK202000 and ZK200775 protected rodent brain against sequelae of permanent occlusion of the middle cerebral artery and head trauma. "
4.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/01/1998 - "Furthermore, delayed treatment with ZK200775 commencing 2 h after onset of reperfusion in transient middle cerebral artery occlusion resulted in a dramatic reduction of the infarct size. "
5.	Wounds and Injuries (Trauma) 09/01/1998 - "ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma."

Related Drugs and Biologics

1.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
2.	Organophosphonates (Phosphonates)
3.	Neuroprotective Agents
4.	AMPA Receptors (AMPA Receptor)
5.	Propionates
6.	Hypnotics and Sedatives (Sedatives)

Related Therapies and Procedures

1.	Treatment Delay